

Supplementary tables

E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer

Ilijana Bajrami^{1,2}, Rebecca Marlow³, Marieke van de Ven⁴, Rachel Brough^{1,2}, Helen N. Pemberton^{1,2}, Jessica Frankum^{1,2}, Fei Fei Song^{1,2}, Rumana Rafiq^{1,2}, Asha Konde^{1,2}, Dragomir B. Krastev^{1,2}, Malini Menon^{1,2}, James Campbell^{1,2}, Aditi Gulati^{1,2}, Rahul Kumar^{1,2}, Stephen J. Pettitt^{1,2}, Mark D. Gurden¹, Marta Llorca Cardenosa^{1,5}, Irene Chong¹, Patrycja Gazinska³, Fredrik Wallberg⁶, Elinor J. Sawyer⁷, Lesley-Ann Martin¹, Mitch Dowsett¹, Spiros Linardopoulos^{1,8}, Rachael Natrajan¹, Colm J. Ryan⁹, Patrick W.B. Derkens¹⁰, Jos Jonkers¹¹, Andrew N.J. Tutt^{1,3}, Alan Ashworth^{12*}, Christopher J. Lord^{1,2*}

Supplementary Table S1 Small molecule inhibitor profiling in CRISPR-Cas9 generated E-cadherin defective MCF7 model. Median surviving fraction, median ratio and *p* value for MCF7 A02 and MCF7 Parental cells are shown.

Small molecule inhibitor ID	Median surviving fraction in MCF7 Parental	Median surviving fraction in MCF7 A02	Median MCF7 A02/Median MCF7 Parental ratio	<i>p</i> value
PF-02341066(MET/ALKi)(1000nM)	0.659	0.256	0.389	0.0004
PF-03758309(PAKi)(1000nM)	0.34	0.136	0.399	0.0001
PF-03758309(PAKi)(100nM)	0.472	0.189	0.4	4.0278E-05
PF-03758309(PAKi)(50nM)	0.393	0.168	0.428	2.5432E-05
PF-03758309(PAKi)(5nM)	0.518	0.226	0.436	0.0002032
BEZ-235(PI3K/mTORi)(500nM)	0.333	0.15	0.449	0.0011
BI-2536(PLKi)(100nM)	0.294	0.134	0.457	0.0071
PF-03814735(Aurora)(100nM)	1.078	0.498	0.462	0.0002
gemcitabine.HCl(DNARepinhb)(50nM)	0.287	0.134	0.467	9.5427E-06
PF-02341066(MET/ALKi)(500nM)	0.789	0.372	0.472	0.0002
gemcitabine.HCl(DNARepinhb)(500nM)	0.272	0.129	0.473	0.0022
crizotinib(ALKi)(500nM)	0.769	0.379	0.493	0.0002
crizotinib(ALKi)(1000nM)	0.605	0.298	0.493	0.0032
PF-03758309(PAKi)(10nM)	0.687	0.341	0.496	0.0001
paclitaxel(microtubulepoison)(1000nM)	0.26	0.129	0.496	0.0137
Foretinib(METi,VEGFR2i,KDRi)(500nM)	0.781	0.39	0.499	0.0072
gemcitabine.HCl(DNARepinhb)(100nM)	0.286	0.146	0.511	0.0002
BEZ-235(PI3K/mTORi)(1000nM)	0.28	0.143	0.512	0.0002
Foretinib(METi,VEGFR2i,KDRi)(1000nM)	0.734	0.382	0.521	0.0001
MLN-4924(NEDDi)(100nM)	0.33	0.174	0.528	0.0003
PF-03814735(Aurora)(1000nM)	0.792	0.42	0.53	0.0006
paclitaxel(microtubulepoison)(100nM)	0.334	0.179	0.536	0.0031
sunitinib/VEGFR1-3i,PDGFRi,Kiti,CSF1Ri)(1000nM)	0.558	0.313	0.56	0.0051
YM155(Survivin-suppressant)(10nM)	0.376	0.211	0.561	0.0071
paclitaxel(microtubulepoison)(10nM)	0.379	0.214	0.566	0.0008
YM155(Survivin-suppressant)(5nM)	0.793	0.45	0.568	0.0008
paclitaxel(microtubulepoison)(5nM)	0.449	0.256	0.57	0.0215
(S)+camptothecin(TOPOLpoison)(50nM)	0.366	0.211	0.578	0.0003
PLX-4720(BRAFi)(0.5nM)	1.057	0.611	0.578	0.0011
BEZ-235(PI3K/mTORi)(100nM)	1.085	0.629	0.579	0.0021
paclitaxel(microtubulepoison)(50nM)	0.304	0.179	0.59	0.0028
PF-04929113(HSP90i)(50nM)	0.53	0.317	0.597	0.0041
sunitinib/VEGFR1-3i,PDGFRi,Kiti,CSF1Ri)(10nM)	1.109	0.667	0.601	0.0011
Istaurotinib(1mM)(JAK2/FLT3/TrkAi)(200nM)	0.873	0.527	0.604	0.0069
(S)+camptothecin(TOPOLpoison)(100nM)	0.284	0.172	0.606	0.0009
sapacitabine(CNDAC)(1000nM)	0.647	0.401	0.619	0.0035
etoposide(TOPOLii)(1000nM)	0.524	0.335	0.638	0.0016
BMN-673(PARPi)(100nM)	0.713	0.456	0.64	0.0014
PF-04929113(HSP90i)(100nM)	0.261	0.168	0.641	0.0126
BMN-673(PARPi)(500nM)	0.626	0.404	0.645	0.0009
PF-03814735(Aurora)(500nM)	0.989	0.641	0.648	0.0001
MLN-4924(NEDDi)(50nM)	0.418	0.272	0.65	0.0022
Sapacitabine(CNDAC)(500nM)	0.762	0.499	0.656	0.0043
DMX_2320(IKKeinhibitor)(1000nM)	0.975	0.641	0.657	0.0196
sapacitabine(CNDAC)(10nM)	0.887	0.586	0.661	0.0278
etoposide(TOPOLii)(500nM)	0.576	0.382	0.663	0.0006
(S)+camptothecin(TOPOLpoison)(0.5nM)	0.836	0.562	0.672	0.0421
BMN-673(PARPi)(1000nM)	0.62	0.421	0.679	0.002
gemcitabine.HCl(DNARepinhb)(10nM)	0.292	0.206	0.708	0.0232
5-FU(anti-metabolite)(1000nM)	0.894	0.634	0.709	0.0024
doxorubicin.HCl(DNAintercalator)(50nM)	0.351	0.25	0.712	0.001
BMN-673(PARPi)(50nM)	0.703	0.502	0.714	0.0037
methotrexate(10nM)	1.107	0.818	0.739	0.0034
(S)+camptothecin(TOPOLpoison)(10nM)	0.603	0.446	0.74	0.0103
17-AAG(HSP90i)(50nM)	0.364	0.272	0.749	0.0068

Supplementary Table S2 Summary table of drug screen AUC, AUC ratios and *p* values for MCF7 A02 and MCF7 Parental isogenic cells

Small molecule inhibitor ID	MCF7 A02	MCF7	MCF7 A02	<i>p</i> value
	median AUC	Parental median AUC	AUC/MCF7 Parental AUC ratio	
PF-03758309(PAKi)	135.3	311.4	0.43	0.0000056
gemcitabine.HCl(DNArepinhib)	146.3	273.9	0.53	0.0000535
paclitaxel(microtubulepoison)	154.5	266.4	0.58	0.0012748
BEZ-235(PI3K/mTORi)	327.3	551.9	0.59	0.0006430
PF-03814735(Aurora)	577.6	961.8	0.60	0.0000959
MLN-4924(NEDDi)	156.4	238.9	0.65	0.0026734
BMN-673(PARPi)	431.4	656.6	0.66	0.0002943
Camptothecin(TOPOLpoison)	83.83	127.4	0.66	0.0000090
Foretinib(METi,VEGFR2i,KDRi)	591	879.5	0.67	0.0073153
Everolimus(mTORi)	911	1353	0.67	0.0000939
PF-04691502(PI3K/mTORi)	228.6	336.7	0.68	0.0071079
PF-02341066(METi/ALKi)	577.4	831.6	0.69	0.0004426
Crizotinib(ALKi)	625.2	879.1	0.71	0.0000970
Flavopiridol(CDKi)	149	204.2	0.73	0.0194037
Doxorubicin(DNAintercalator)	100.4	136.9	0.73	0.0029741
PF-04929113(HSP90i)	146.1	196	0.75	0.0013952
17-AAG(HSP90i)	124.6	167.1	0.75	0.0116781
PF-332991(CDK4/6i)	1070	1430	0.75	0.0015142
RO-3306(CDK1i)	1027	1279	0.80	0.0301231
Sapacitabine(CNDAC)	686.4	842.9	0.81	0.0180510
Etoposide(TOPOLii)	702.7	854	0.82	0.0018328
MK2206(AKTi)	1131	1349	0.84	0.0118299
YM155(Survivin-suppressant)	31.61	37.58	0.84	0.0042925
GSK2194069A(FASI)	2113	2505	0.84	0.0210857
Methotrexate	676.6	767.1	0.88	0.0180580
Sorafenib(inhibitsRAF,PDGF,VEGF1&2)	1114	1026	1.09	0.0492614
Salinomycin(microtubulepoison)	1305	730.3	1.79	0.0001269

Supplementary Table S3 RNAi screen in CRISPR-Cas9 generated E-cadherin defective model. The difference in Z-score data of median of E-cadherin defective and median of wt. groups are shown.

GeneID	Median Z score Parental	Median Z score A02	Difference In Z score	Students t-test	GeneID	Median Z score Parental	Median Z score A02	Difference In Z score	Students t-test
PM81	-0.37868745	-8.98291435	-8.6042269	0.000157058	NPM1	-1.11536265	-4.70782033	-3.59245769	0.045643175
KIT	-0.51398672	-8.83138319	-8.31739647	3.23471E-06	PDCD1LG2	-1.42689663	-5.00114015	-3.57424351	0.012844291
CHIC2	-0.24934777	-7.56700148	-7.31766371	0.000491343	PLA61	-1.36229198	-4.88575082	-3.52345884	0.00019456
FBXO11	-0.47643587	-7.75906429	-7.28262842	5.75639E-05	FANCG	-0.52069173	-4.00109819	-3.48040646	0.000432207
PRKAR2B	-0.22223177	-7.3524416	-7.13020984	0.00377432	HOXC11	1.125960451	-2.28970679	-3.41566725	0.000106356
DCLRE1A	-1.15851394	-7.98333021	-6.82481627	0.00061272	DDIT3	-1.04256821	-4.32625127	-3.28368306	0.017071472
KMT2C	-1.15948954	-7.97654051	-6.81705097	1.74845E-05	CDK12	-0.1036177	-3.37288538	-3.26925757	0.038503948
CSNK1A1	-1.24075613	-7.72050314	-6.47974701	0.000216709	FANCB	-0.38206882	-3.61986303	-3.23779421	0.040548552
H3F3A	1.227762649	-5.0679676	-6.29573025	0.005129908	MERTK	-0.81953587	-3.87690355	-3.05736768	0.01453234
INSRR	-1.48048109	-7.77183138	-6.29135029	0.00020486	RECQL	-0.41383062	-3.42166959	-3.00783897	0.005132054
PIM1	0.384101613	-5.87138389	-6.25548551	0.000381328	CREB3L2	-1.13816631	-4.1443255	-3.00615918	0.002602646
FLJ21816	-1.43658773	-7.64235611	-6.20576838	0.000201037	KDM6A	-0.630123955	-3.63258606	-3.00284651	0.002065989
EBF1	0.776518801	-5.34505678	-6.12157558	0.015351369	CLTC	-1.30341603	-4.22631583	-2.92289979	0.000861809
UBR5	-1.28318069	-7.35090876	-6.06772807	9.81113E-05	NUTM1	0.424446202	-2.27999357	-2.70443987	0.011105984
CRK7	-0.48822231	-6.35016686	-5.86194455	0.001680351	GALK1	-0.46920544	-3.14914839	-2.67994295	0.004391752
CCDC65	-1.42492956	-7.06507291	-5.64014335	0.000156725	CDC2L1	-0.87741537	-3.52404619	-2.64663082	0.002303834
HUNK	-1.4630816	-7.04536056	-5.58227896	0.000488868	CPNE3	-0.50139866	-3.10907394	-2.60767528	0.044875919
DGUOK	0.6508288892	-4.85190435	-5.50273324	0.000314777	CRTC3	0.362399679	-2.15448416	-2.51688384	0.005290478
COC2	-0.72278912	-6.21507314	-5.49228402	0.00022434	MITF	0.34934652	-2.13805273	-2.48739925	0.008902537
ATRIP	0.362360903	-5.12057518	-5.48293608	0.000538097	TREX2	-1.23565199	-3.67032532	-2.43467332	0.004135544
WRN	-0.98830613	-6.47105232	-5.482747462	0.001924952	SMARCE1	-0.40796467	-2.82778089	-2.41981622	0.043945748
CTNNB1	-0.63465189	-6.03550606	-5.40085417	0.0005050959	PAK4	-1.50379621	-3.89188488	-2.38808866	0.004455848
KMT2D	-1.33572548	-6.72874917	-5.39302369	0.000396323	POLH	-1.07087282	-3.39267782	-2.32180499	1.08771E-05
RUNX1	-0.82421605	-6.1880993	-5.36388325	0.000805091	MYLK2	-0.95124097	-3.26527182	-2.31403085	8.27814E-05
AAK1	-0.33184708	-5.69220545	-5.36035836	0.000973975	C10ORF89	-1.14154789	-3.41840933	-2.27686144	0.034933398
PRKCN	0.570560407	-4.75171683	-5.32237724	0.009811467	SETD2	-1.08157534	-3.35432983	-2.27275449	0.000327971
GATA1	-0.98775391	-6.28738778	-5.29963387	0.001862397	LMTK3	-1.25882889	-3.5221478	-2.26331891	0.000174692
SBK1	-0.73078421	-5.95632222	-5.22553799	0.001572046	DCK	-0.87783821	-3.14074738	-2.26290917	0.005743764
MAP2K7	-0.8058538	-5.97229345	-5.16643965	0.000376876	FLT4	0.113209615	-2.1488326	-2.26204222	0.049605366
PFKFB4	-0.54389259	-5.57442057	-5.03152797	0.020316338	CSF1R	-1.25867281	-3.49019105	-2.23151824	0.026100848
ARID1A	-0.60278036	-5.21603205	-4.9728169	0.005199919	PCNA	-0.95920804	-3.16452046	-2.20531242	0.023688738
MSH3	-0.76262113	-5.67603399	-4.91341286	0.001794646	USP6	-0.59633921	-2.71606527	-2.16472607	0.0198516483
TRIM24	-0.47812214	-5.38892315	-4.910801	0.000382544	PNUTL1	-0.90801383	-3.06208253	-2.1540687	0.048633502
STK38L	-0.67035213	-5.49776299	-4.82741086	0.004361046	TOPBP1	-1.44774262	-3.5871968	-2.13945418	0.008390008
DOX5	-1.35126216	-6.12012632	-4.76889002	0.000141545	ARAF1	0.047569234	-2.0269218	-2.07449103	0.036405259
PRDM16	0.78940912	-3.97140585	-4.76081497	0.019166968	MN1	-0.41296756	-2.4427168	-2.02974923	0.001726923
RP66KA2	-1.25391289	-5.98601505	-4.73210216	0.000796379	PIK3C2A	-1.46227691	-3.48384269	-2.02156578	0.00665146
TGFBR1	0.409488382	-4.30637608	-4.71586447	0.011352904					
EPHA4	-0.9245529	-5.60847235	-4.68391945	0.002335804					
RPA3	-1.38333275	-6.04486487	-4.66153212	8.77224E-05					
TRIP11	0.005157012	-4.63756233	-4.64271934	0.024706798					
PFKP	-0.67442115	-5.21603922	-4.54161807	0.045371638					
ADP-GK	-0.97323477	-5.48985303	-4.51661827	0.001854579					
POT1	-1.36896822	-5.88109006	-4.51212183	0.000146199					
NEK4	-0.08598567	-4.57934673	-4.49336106	0.033345167					
GTF2H4	-0.27520057	-4.72076013	-4.44555957	0.002583076					
ADCK4	0.333301162	-4.03184327	-4.36514444	0.017771881					
GTF2H1	-0.6274943	-4.90083955	-4.27334525	0.011279748					
PLK1	-1.01026031	-5.20775162	-4.19749131	0.001593987					
PTEN	0.42616659	-3.70382457	-4.12999115	0.001203126					
AK5	-1.173301	-5.28589924	-4.11259824	0.010069924					
ATF1	0.083926536	-4.00854044	-4.09246697	0.000411106					
ZBTB16	0.215516313	-3.82420709	-4.03972341	0.015400172					
GRK4	-1.34929841	-5.35582664	-4.006552822	0.000498204					
PLK3	-1.29844066	-5.25143729	-3.95299664	0.004324462					
FYN	-1.31220116	-5.2442765	-3.93207534	0.002023798					
ROS1	-0.49442849	-4.34423518	-3.84980669	0.030213832					
POLM	-0.44870629	-4.29010774	-3.84140145	0.000297354					
FANCI	-0.8100862	-4.63999479	-3.82989659	0.053240715					
DAXX	0.821090414	-2.99236049	-3.8134509	0.000897737					
PRKAG3	-1.360728	-5.1598619	-3.7991339	0.000970212					
FEV	-1.17576063	-4.96998454	-3.79422401	0.00116181					
S6X2	-1.02529557	-4.81330784	-3.78801227	0.007729931					
CLK3	-0.58729081	-4.34366846	-3.75637765	0.009591982					
PRKCB1	-1.50048056	-5.25292696	-3.75244464	0.000158787					
FES	-0.39210366	-4.1442883	-3.75218464	0.008493374					
MSH4	-0.30542159	-4.04339584	-3.73797426	0.013932418					

Supplementary Table S4 Gene ontology analysis of a list of 104 genes identified as E-cadherin synthetic lethal targets using EnrichR analysis.

Name	P-value	Adjusted p-value	Z-score	Combined score	Genes involved
RNA polymerase II carboxy-terminal domain kinase activity	3.48E-13	1.60E-10	-3.19	91.47	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, TGFBR1, GTF2H1, GTF2H4, CDK12
protein serine/threonine kinase activity	5.29E-13	1.60E-10	-3.21	90.66	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, GTF2H1, GTF2H4, CDK12, EPHA4
myosin light chain kinase activity	4.24E-11	8.52E-09	-3.16	75.5	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, TGFBR1, MYLK2
calmodulin-dependent protein kinase activity	5.87E-11	8.85E-09	-3.11	73.37	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, TGFBR1, GTF2H1, GTF2H4, CDK12
cyclin-dependent protein serine/threonine kinase activity	8.44E-11	1.02E-08	-3.12	72.41	
cyclic nucleotide-dependent protein kinase activity	4.11E-10	1.35E-08	-3.06	66.21	
transmembrane receptor protein serine/threonine kinase activity	4.29E-10	1.35E-08	-3.06	65.99	
GTP-dependent protein kinase activity	4.11E-10	1.35E-08	-3.05	65.96	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, TGFBR1
Rho-dependent protein serine/threonine kinase activity	4.11E-10	1.35E-08	-3.04	65.81	PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, TGFBR1
ribosomal protein S6 kinase activity	4.11E-10	1.35E-08	-3.04	65.72	
protein kinase C activity	4.49E-10	1.35E-08	-3.05	65.71	
histone threonine kinase activity	4.29E-10	1.35E-08	-3.04	65.63	
3-phosphoinositide-dependent protein kinase activity	4.11E-10	1.35E-08	-3.04	65.62	
eukaryotic translation initiation factor 2alpha kinase activity	4.29E-10	1.35E-08	-3.04	65.59	
DNA-dependent protein kinase activity	4.49E-10	1.35E-08	-3.04	65.49	
G-protein coupled receptor kinase activity	4.29E-10	1.35E-08	-3.03	65.43	
histone serine kinase activity	4.69E-10	1.35E-08	-3.05	65.42	
Fas-activated serine/threonine kinase activity	4.11E-10	1.35E-08	-3.03	65.4	
calcium-dependent protein serine/threonine kinase activity	4.29E-10	1.35E-08	-3.03	65.39	
AMP-activated protein kinase activity	4.69E-10	1.35E-08	-3.04	65.37	

Supplementary Table S5 A summary of mutations, mRNA expression, copy number alterations and western blot analysis in a panel of 34 breast cell line models.

Cell line ID	Histology	ccele protein mutations	ccele cDNA mutations	ccele expression n data	ccele data	CN	COSMIC prot mut	COSMIC CDS mut	Sanger expressio n norm	sanger copy number	Western (1=defectiv e, 0=wt)	Call used for analysis
AMP,												
BT20	BREAST	p.I451I	c.1353T>C	10.70444	1.072				1650.961	5	0	0
BT474	BREAST			10.77893	0.0683						0	0
CAMA1	BREAST	p.G571_splice	c.1712_splice	7.893037	0.1527	p.?	c.1712-1G>A	257	2	0	0	0
DU4475	BREAST			7.708805	0.04				376.9675	4	0	0
HCC1143	BREAST			9.936666	-0.1906				905	3	0	0
HCC1954	BREAST			10.09732	0.4385				1622.896	6	0	0
HCC202	BREAST			9.009011	0.1866						0	0
HCC38	BREAST			8.384195	0.0624				1027.918	4	0	0
HCC70	BREAST			9.823594	0.603				1284.946	6	0	0
HMT3552	BREAST										0	0
JIMT1	BREAST			10.27569	-0.2986						0	0
MCF12A	BREAST										0	0
MCF7	BREAST			9.998439	0.0797				1413.805	3	0	0
MDAMB468	BREAST			8.032266	-0.3456				405.8228	2	0	0
SUM149	BREAST										0	0
SUM52	BREAST										0	0
T47D	BREAST			9.600242	0.0838				1474.012	3	0	0
VP229	BREAST										0	0
ZR751	BREAST			8.592579	0.9041						0	0
MCF10A	BREAST										0	0
MFM223	BREAST								1060	2		0
CAL51	BREAST			7.276337	-0.0055				996.4421	2	0	0
BT549	BREAST			4.587023	0.0331				18.20013	2	1	1
CAL120	BREAST			7.52427	-0.0577				69.7	3	1	1
HS578T	BREAST			4.442452	-0.3383				1.92	2	1	1
MDAMB134	BREAST	p.L230_P277del	c.688_832del	6.35283	-0.9568						1	1
MDAMB157	BREAST			4.102815	-0.1466				12.1	4	1	1
MDAMB231	BREAST			4.229351	-0.3833				14.50108	2	1	1
MDAMB436	BREAST			4.367926	-0.5437						1	1
MDAMB453	BREAST	p.W638*		c.1913G>A	6.867313	-0.4483	p.W638*	c.1913G>A	79.1	3	1	1
SKBR3	BREAST			Homozygous deletion		4.490762	-5.279				1	1
SUM159	BREAST										1	1
SUM44	BREAST	p.F423fs*8		c.1269delT							1	1
ZR7530	BREAST	p.E243*		c.727G>T	5.859798	-0.7924	p.E243*	c.727G>T	54.3	2	1	1

Supplementary Table S6 Synthetic lethality in E-cadherin defective breast tumour cell line models. The difference in Z-score data of median of E-cadherin defective and median of wt. groups are shown.

grpA = E-cadherin defective
grpB = E-cadherin wild type

target	med.grpA	med.grpB	med.grpA-med.grpB	min.grpA	min.grpB	mptest.p
CDC42BPA	-2.64176	-0.57186	-2.06990	-5.37019	-5.52563	0.002
PLK4	-2.21741	-1.17528	-1.04213	-6.17464	-5.27888	0.025
MAPKAPK3	-2.07782	-1.04596	-1.03186	-3.64434	-3.02670	0.003
GSK3A	-1.47758	-0.53077	-0.94681	-6.62853	-2.90063	0.026
ROS1	-0.93360	0.00883	-0.94242	-3.35439	-1.85628	0.04
ROCK2	-0.26440	0.58160	-0.84599	-0.70468	-0.78533	0.001
PSKH2	-0.80327	0.01768	-0.82095	-2.50469	-1.55815	0.016
RELA	-1.72711	-0.92667	-0.80044	-3.06619	-3.10870	0.051
STK16	-0.49386	0.28049	-0.77436	-1.27060	-2.34358	0.019
STK33	-0.39610	0.33121	-0.72731	-2.64870	-1.48138	0.034
EPHB3	-0.84407	-0.12037	-0.72370	-2.01908	-2.13862	0.003
PRKCA	-1.15198	-0.43134	-0.72064	-1.87986	-4.19953	0.013
DUSP21	0.04199	0.73586	-0.69388	-1.05428	-0.30027	0.009
HRI	-0.27956	0.39963	-0.67918	-1.45645	-1.25856	0.04
AAK1	-0.67495	-0.01526	-0.65970	-2.49785	-0.67453	0.008
STK23	-0.37167	0.28025	-0.65192	-0.65074	-1.72014	0.052
HIPK2	-0.09839	0.54787	-0.64626	-2.99720	-1.25732	0.028
TEC	0.14326	0.78498	-0.64172	-1.34624	0.05313	0.027
PIK3R2	-0.49107	0.12405	-0.61512	-2.67861	-0.53011	0.008
MAP3K7IP1	0.10123	0.70366	-0.60243	-0.55046	-0.71759	0.043
SNF1LK	0.05268	0.65430	-0.60162	-1.45619	-0.51718	0.037
ACVR2	0.05574	0.64468	-0.58893	-1.76541	-1.16943	0.047
TAO1	-0.18255	0.38160	-0.58415	-1.51591	-0.76176	0.017
PRKAG2	0.21464	0.75624	-0.54160	-0.89369	-0.54274	0.038
YES1	-0.33304	0.19853	-0.53157	-1.62334	-1.21128	0.032
CDKN2B	0.39549	0.92686	-0.53136	-0.68004	0.12244	0.008
ZAK	0.16561	0.68305	-0.51744	-0.80647	-1.00789	0.003
IRAK4	0.10837	0.58922	-0.48085	-1.02341	-0.99621	0.047
CAMK1G	0.32019	0.78996	-0.46977	-0.80620	-0.36789	0.035
DYRK1A	-0.24752	0.19443	-0.44195	-1.10156	-2.35672	0.026
CHEK2	0.23970	0.63783	-0.39812	-0.97307	-1.14818	0.009

Supplementary Table S7 Synthetic lethality in E-cadherin defective mixed histology tumour cell line models. The difference in Z-score data of median of E-cadherin defective and median of wt. groups are shown.

grpA = E-cadherin defective
grpB = E-cadherin wild type

target	med.grpA	med.grpB	med.grpA-med.grpB	min.grpA	min.grpB	mp-test.p
TGFBR2	-1.343274	0.138601	-1.381875	-2.997574	-2.562569	0
KSR1	-1.679058	-0.418926	-1.260132	-5.513046	-4.779142	0
STK39	-2.452338	-1.247593	-1.204745	-6.440513	-5.665470	0.007
P14KA	-0.925708	0.164015	-1.090723	-2.970935	-2.165499	0
PTK7	-2.165658	-1.119660	-1.045998	-8.527493	-6.414201	0.034
GALK2	-1.325077	-0.406614	-0.918463	-6.318603	-3.502433	0.047
ERN1	-1.118289	-0.220308	-0.897981	-5.740674	-3.347093	0.039
DGCR14	-0.730032	0.094997	-0.825029	-4.693139	-2.202150	0.004
DGKI	-0.058328	0.750789	-0.809117	-4.511130	-1.777454	0
PDGFRA	-0.502712	0.305059	-0.807771	-2.788124	-1.922740	0.001
ADRBK1	-0.971987	-0.170078	-0.801909	-2.185112	-3.181181	0.015
PDK4	-0.660132	0.135210	-0.795342	-3.948641	-2.708407	0.008
TEX14	-0.742206	0.046444	-0.788650	-3.555046	-2.051626	0.026
NEK8	-1.920802	-1.156005	-0.764795	-4.725576	-5.894615	0.047
C8NCQ9	-1.480597	-0.724058	-0.756539	-4.335044	-3.696255	0.002
HIPK2	-0.237391	0.502075	-0.739465	-2.205681	-1.609760	0.002
DGKQ	-1.654579	-0.943299	-0.711380	-11.845917	-5.255620	0.012
ACVR2B	-0.631440	0.075280	-0.706720	-3.556247	-2.754110	0.02
RELA	-2.065971	-1.381996	-0.683875	-5.379719	-3.322088	0.025
TE8K1	-0.694235	-0.052710	-0.641525	-3.121612	-1.827845	0.004
STK33	-0.926057	-0.285008	-0.641049	-4.497377	-1.866116	0
RP86KAS	-0.857149	-0.232182	-0.624967	-2.728001	-2.498135	0.042
DYRK1B	0.056933	0.675336	-0.618404	-1.190798	-1.486860	0.003
MARCK3	-1.465187	-0.851111	-0.614076	-7.416331	-3.089232	0.008
TSSK3	-1.078410	-0.474033	-0.604377	-3.631533	-2.452670	0.007
PRKDC	-0.883021	-0.279376	-0.603645	-4.243728	-2.543423	0.013
MAP2K1	-0.150412	0.451418	-0.601830	-2.007355	-1.758468	0.008
PAP882	-0.116934	0.482086	-0.599020	-2.160100	-1.224303	0.011
SYK	-1.216762	-0.621014	-0.595747	-5.717837	-3.609074	0.018
DMPK	-0.846393	-0.303005	-0.543388	-2.510067	-2.156521	0.03
PIK3RS	-0.692260	-0.149402	-0.542858	-3.590491	-2.271940	0.05
PRKFB4	-0.431352	0.101159	-0.532512	-2.910369	-2.006308	0.029
ABL2	-0.291865	0.222316	-0.514181	-3.027379	-2.202006	0.032
PRKCH	-1.231438	-0.734734	-0.496704	-7.005438	-4.782421	0.01
RO81	-0.865455	-0.369936	-0.495519	-4.880350	-1.922964	0.018
INSR	-0.841129	-0.359605	-0.481523	-5.000156	-2.754405	0.017
SGK494	0.000530	0.462871	-0.462341	-1.779279	-2.218415	0.047
RP86KL1	-1.100377	-0.641046	-0.459330	-5.578052	-4.386062	0.023
RNAEL	0.001219	0.446264	-0.445044	-1.725733	-0.762448	0.038
SPHK1	-0.662750	-0.229248	-0.433501	-2.856694	-3.705312	0.024
CDKL2	-0.553056	-0.149727	-0.403329	-3.325781	-2.094427	0.023
IKBKAP	0.228990	0.631039	-0.402049	-1.438710	-1.067847	0.047
CDKS	-0.193360	0.205544	-0.398904	-2.385988	-1.410798	0.031
PANK2	-0.075430	0.320886	-0.396316	-2.204769	-0.351271	0.015
ATR	-0.824295	-0.434661	-0.389635	-3.210269	-2.610254	0.054
CKS1B	0.140897	0.524611	-0.383714	-1.652039	-1.220660	0.018
ITPKC	0.154354	0.521787	-0.367433	-1.623605	-0.680141	0.034
EIF2AK3	0.543862	0.321654	0.222208	-1.818900	-2.604610	0.024
RIPK3	0.430480	0.186146	0.244334	-0.895032	-1.853933	0.053
PAK5	0.569676	0.260049	0.309627	-0.763488	-2.366362	0.029
MAST1	-0.149406	-0.475622	0.326215	-2.242699	-3.619800	0.017
MAK	0.177387	-0.152060	0.329447	-0.873301	-2.391710	0.04
BMX	0.734513	0.402102	0.332411	-1.213764	-1.243430	0.044
GK2	0.584713	0.251732	0.332980	-0.651581	-1.316440	0.046
MLTK	0.847545	0.489719	0.357826	-1.490000	-1.173233	0.019
CAMKK1	0.873687	0.514153	0.359534	-0.218984	-6.484650	0.05
FXN	0.824474	0.460452	0.364022	-0.107796	-1.000000	0.041
STK10	0.225717	-0.140088	0.365806	-1.385076	-2.225885	0.023
DL02	0.899179	0.526510	0.372669	-0.990287	-1.250076	0.031
RYK	0.841602	0.445273	0.396329	-0.961652	-0.922224	0.011
CHKB	0.708232	0.309908	0.398334	-0.826940	-1.492716	0.011
TLK2	0.641715	0.242506	0.399208	-0.463055	-1.942379	0.046
XRC06BP1	0.408797	-0.012229	0.421026	-1.716343	-1.373838	0.038
ITPKB	0.010137	-0.418758	0.428895	-0.967109	-2.516106	0.029
COMM3D	-0.423298	-0.872774	0.449476	-3.024309	-4.354284	0.038
GRK1	0.636621	0.172336	0.464285	-1.054254	-1.010654	0.01
CAMK2G	0.520000	0.029266	0.490734	-2.765941	-6.807591	0.001
PIK3CD	0.445943	-0.047794	0.493736	-2.420122	-2.552814	0.004
P14K2A	0.613821	0.112399	0.501422	-1.113786	-2.302300	0.012
CDKL5	0.488426	-0.020762	0.509188	-2.401872	-5.030140	0.029
RFK	0.562565	0.051000	0.511565	-11.218788	-3.239306	0.012
PAK3	-0.079431	-0.591682	0.512251	-2.787965	-1.583351	0.037
BLK	0.744972	0.229039	0.515934	-1.095004	-1.667110	0.019
XYLB	0.485913	-0.049250	0.535163	-0.814253	-1.881183	0.01
MAP4K2	-0.122674	-0.686796	0.564122	-6.431871	-3.729617	0.019
SCYL3	-0.212622	-0.792468	0.579846	-1.852586	-3.104754	0.005
PRKCD	0.020193	-0.569266	0.589461	-1.982389	-3.635411	0.026
PRKCE	0.175195	-0.429886	0.605081	-2.068204	-2.601848	0.02
FLT1	0.541576	-0.065291	0.606867	-0.687280	-1.980176	0.012
PIK3CA	0.632857	0.009453	0.623404	-2.095434	-3.346469	0.041
PRKACB	0.416099	-0.282455	0.698955	-0.786927	-4.714100	0
NRBP1	-0.154594	-0.867996	0.713442	-6.548961	-3.688949	0.014
MAP3K2	0.997364	0.235848	0.761516	-9.240182	-4.313790	0

Supplementary Table S8 Individual area under the curve (AUC) and surviving fraction 50 (SF₅₀) values of foretinib or crizotinib in 12 breast tumour cell lines.

Cell line name	E-cadherin Defective/WT	IC50 foretinib μM	IC50 crizotinib μM	AUC foretinib	AUC crizotinib
SKBR3	Defective	0.013833975	0.016801266	1.088	1.3
SUM44	Defective	0.042514101	0.032861168	1.112	1.162
CAL120	Defective	0.226411249	0.95616975	1.574	2.101
BT549	Defective	0.251779887	0.995070841	1.492	1.939
MDAMB157	Defective	0.828827209	2.943459062	2.08	2.532
MDAMB231	Defective	0.918108483	1.623166235	2.15	2.411
MFM223	WT	0.742138565	2.353282147	1.941	2.432
T47D	WT	1.010231718	1.010231718	2.04	2.04
SUM149	WT	1.103171415	3.184439483	2.674	2.563
MCF7	WT	2.309787358	2.369119678	2.794	2.848
MCF12A	WT	2.461943036	3.460987255	2.678	2.904
MCF10A	WT	2.682402839	3.772671576	2.673	2.981

Supplementary Table S9 ROS1 genomic alterations in breast tumour cell lines.

Cell line name	E-cadherin status	ROS1 fusions data by Klijn et al 2015	CCLE/COSMIC ROS1 amplifications/deletions	COSMIC ROS1 mutations	CCLE ROS1 mutations
BT20_BREAST	E-cadherin wild type	not detected	AMP	not detected	p.D618E
BT474_BREAST	E-cadherin wild type	not detected	not detected	p.V1916L	p.V1916L
BT549_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
CAL120_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
CAL51_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
CAMA1_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
DU4475_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HCC1143_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HCC1954_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HCC202_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HCC38_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HCC70_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
HMT3552_BREAST	E-cadherin wild type	not assessed	not detected	not detected	not detected
HS578T_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
JIMT1_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
MCF10A_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
MCF12A_BREAST	E-cadherin wild type	not assessed	not detected	not detected	not detected
MCF7_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
MDAMB134VI_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
MDAMB157_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
MDAMB231_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
MDAMB436_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
MDAMB453_BREAST	E-cadherin defective	not detected	not detected	p.V1971V	not detected
MDAMB468_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
MFM223_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
SKBR3_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
SUM_149_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
SUM_159_BREAST	E-cadherin defective	not detected	not detected	not detected	not detected
SUM_44_BREAST	E-cadherin defective	not assessed	not detected	not detected	not detected
SUM_52_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
T47D_BREAST	E-cadherin wild type	not detected	not detected	not detected	not detected
VP229_BREAST	E-cadherin wild type	not assessed	not detected	not detected	not detected
ZR751_BREAST	E-cadherin wild type	not detected	HOMDEL	not detected	not detected
ZR7530_BREAST	E-cadherin defective	not detected	not detected	not detected	p.K2099N
HCC78	Control cell line harbouring a ROS1 fusion	SLC34A2-ROS1			

Supplementary Table S10 Small molecule inhibitor library. List of 80 compounds and their molecular targets.

Drugs	Target	Company	Clinical Stage
4-OH-TAMOXIFEN	ER	Off patent generic drug	Licensed
5-FU	DNA	Off patent generic drug	Licensed
6-THIOGUANINE	DNA	GSK	Licensed
ABIRATERONE	CYP17A1	J and J	Licensed
BIBW2992	EGFR/ERBB2	Boehringer Ingelheim	Licensed
BLEOMYCINSULFATE	DNA	BMS	Licensed
CABOZANTINIB	cMET,VEGFR	Exelixis	Licensed
CAMPTOTHECIN	TOPO I/polo1n	Off patent generic drug	Licensed
CARBOPLATIN	DNA	BMS	Licensed
CELECOXIB	COX2	Pfizer	Licensed
DASATINIB	SRC	BMS	Licensed
DECITABINE	DNA	Janssen-Cilag	Licensed
DOXORUBICIN.HCL	DNA	Off patent generic drug	Licensed
ERLOTINIB	EGFR	Genentech	Licensed
ETOPOSIDE	Topoisomerase	Off patent generic drug	Licensed
EVEROLIMUS	mTOR	Novartis	Licensed
GDC-0449	Hedgehog	Genentech	Licensed
GEFITINIB	EGFR	AZ	Licensed
GEMCITABINE.HCL	DNA	Eli Lilly	Licensed
IMATINIBMESYLATE	ABL	Novartis	Licensed
MDV-3100	AR	Medivation	Licensed
METHOTREXATE	DHFR	Off patent generic drug	Licensed
nilotinib	ABL	Novartis	Licensed
olaparib	PARP1/2	AZ	Licensed
paclitaxel	Microtubules	Off patent generic drug	Licensed
PLX-4720	BRAF	Plexicon	Licensed
sorafenib	VEGF, PDGFR	Bayer	Licensed
sunitinib	RTKs	Pfizer	Licensed
temozolamide	DNA	Schering	Licensed
vinorelbine	Microtubules	Off patent generic drug	Licensed
voronostat	HDACs	Merck	Licensed
MK-1175	WEE1	Merck	Phase 1
MLN-4924	NAE	Millenium	Phase 1
Nutlin3	p53	Roche	Phase 1
PF-00477736	CHEK1	Pfizer	Phase 1
PF-03758309	PAK4	Pfizer	Phase 1
PF-04929113	HSP	Pfizer	Phase 1
SAR-20106	CHKs	ICR	Phase 1
BI-2536	PLK1	Boehringer Ingelheim	Phase 2
17-AAG	HSP90	BMS	Phase 2
2-METHOXYESTRADIOL	ER	Entremed	Phase 2
ABT-737	BCL2	Abbott	Phase 2
AZ4547	FGFRs	AZ	Phase 2
BEZ-235	mTOR/PI3K	Novartis	Phase 2
BMN-673	PARP1/2	Blomarin	Phase 2
BMS-911543	JAK2	BMS	Phase 2
CANERTINIB	panERBB	Pfizer	Phase 2
FLAVOPIRIDOL	CDKs	Sanofi	Phase 2
FOREGINIB	cMET, VEGFR	Exelixis/GSK	Phase 2
LESTAURTINIB	JAK	Cephalon	Phase 2
MK0752	Gamma Secretase	Merck	Phase 2
MK2206	AKT	Merck	Phase 2
PF-00299804	EGFR	Pfizer	Phase 2
PF-03814735	AURK	Pfizer	Phase 2
AG-14699	PARP1/2	Pfizer/Clovis	Phase 3
CRIZOTINIB	ALK,ROS1	Pfizer	Phase 3
LAPATINIB	ERBB	GSK	Phase 3
LENVATINIB	VEGF	Eisai	Phase 3
OSI-906	IGF1R	OSI	Phase 3
PD-0332991	CDK4/6	Pfizer	Phase 3
PF-02341066	MET/ALK1	Pfizer	Phase 3
PF-04691502	PI3K	Pfizer	Phase 3
PF-332991	CDK4/6	Pfizer	Phase 3
Sapacitabine	DNA	Medivation	Phase 3
ICR_1783	Tankyrase	ICR	Pre-clinical
ICR_1913	Tankyrase	ICR	Pre-clinical
GSK-2334470A	PDK1	GSK	Pre-clinical
GSK1904529A	IGF1R	GSK	Pre-clinical
GSK2194069A	FASIN	GSK	Pre-clinical
KU0057788	DNAPKCs	AZ	Pre-clinical
KU60019	ATM	AZ	Pre-clinical
MSC2358705A	DNA-Pk	Merck	Pre-clinical
PD-184352	MEK	Pfizer	Pre-clinical
PD173074	FGFRs	Pfizer	Pre-clinical
resveratrol	SIRTs	Off patent	Pre-clinical
RO-3306	CDKs	Off patent	Pre-clinical
sallomycin	n/k	Off patent	Pre-clinical
Sobstauroin/AEB071	PKC	Novartis	Pre-clinical
XAV-939	Tankyrase	Novartis	Pre-clinical
YM155	Survivin	positive control for screen	Pre-clinical

Supplementary Table S11 Summary of antibodies used in this study. This table lists the antibodies used, supplier and antibody dilution.

Antibody	Supplier	Product Number	Dilution
E-cadherin	Cell signalling	3195	1/1000
ACTIN	Santa Cruz	sc-1616	1/1000
EZRIN	Cell signalling	3145	1/1000
α Tubulin	Santa Cruz	sc-5286	1/1000
Phalloidin	Thermofisher Scientific	A12379	1/500
MRCK α	GeneTex	GTX102598	1/1000
pH2AX	Millipore	05-636	1/1000
MKLP1	Santa Cruz	SC-857	1/200
Catenin δ -1 Antibody	Cell signalling	4989	1/1000
Phospho-Catenin δ -1 (Tyr228)	Cell signalling	2911	1/1000
Phospho-Catenin δ -1 (Ser320)	Cell signalling	8016	1/1000
PARP1	Santa Cruz	sc-8007	1/200
p21	Cell signalling	2947	1/1000
anti-FLAG	Sigma-Aldrich	F3185	1/1000
ROS1	Cell signalling	3287	1/1000
anti-p120	BD Biosciences	610134	1/500
MET	Cell signalling	8198	1/1000
ALK	Cell signalling	3633	1/1000
Akt	Cell signalling	9272	1/1000
Phospho-Akt (Ser473)	Cell signalling	4060	1/1000
Phospho-p44/42 MAPK	Cell signalling	4370	1/1000
p44/42 MAPK	Cell signalling	4695	1/1000
Phospho-ROS1 (Tyr2274)	Cell signalling	3078	1/1000